{"schema_version":"secwatch.filing_event.v1","accession":"0001472375-25-000037","form_type":"8-K","ticker":"RGPX","cik":"0001357878","company_name":"REGENEREX PHARMA, INC.","filed_at":"2025-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.058743+00:00","generated_at":"2026-05-23T23:18:25.073597+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Regenerex Pharma appoints Kenneth Perry as CFO; Brent Wilson resigns effective March 31, 2025","bullets":["Kenneth W. Perry appointed CFO effective March 31, 2025; 39 years of healthcare finance experience.","Brent Wilson resigned as CFO on March 31, 2025, citing personal reasons.","Perry holds an MBA in Finance from Mississippi State and a BS in Accounting from Tennessee Tech.","Previously served as Division CFO for HCA and founded Lasis Healthcare; multiple award-winning CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001472375-25-000037","json":"https://secwatch.observer/filing/0001472375-25-000037.json","markdown":"https://secwatch.observer/filing/0001472375-25-000037.md","text":"https://secwatch.observer/filing/0001472375-25-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357878/000147237525000037/0001472375-25-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357878/000147237525000037/ixform8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T23:18:25.073597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"621e88f058","claim":"Brent Wilson resigned as Chief Financial Officer at REGENEREX PHARMA, INC..","evidence_excerpt":"Effective March 31, 2025, Mr. Brent Wilson resigned his position as Chief Financial Officer of the Company due to personal reasons.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357878/000147237525000037/0001472375-25-000037-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"d95950ea1f","claim":"Kenneth W. Perry was appointed as Chief Financial Officer at REGENEREX PHARMA, INC..","evidence_excerpt":"Effective March 31, 2025, Mr. Kenneth W. Perry has been appointed to serve as Chief Financial Officer for the company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357878/000147237525000037/0001472375-25-000037-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}